Novo Holdings Sells 1.6M MapLight Shares, Stake Falls Below 5%

summarizeSummary

Novo Holdings A/S sold 1.6 million MapLight shares, dropping its stake below 5% and ceasing to be a 5% beneficial owner. The sale follows mixed clinical data and a CFO departure.

check_boxKey Events · Ownership and Investor Activity · MPLT

• Novo Holdings Sells 1.6M Shares

  On July 30, 2026, Novo Holdings A/S sold 1,600,000 shares in three tranches: 1,314,195 shares at $12.00, 220,723 shares at a weighted-average price of $14.19, and 65,082 shares at a weighted-average price of $14.69, generating total proceeds of approximately $20.8 million.

• Stake Drops Below 5%

  After the sale, Novo Holdings A/S beneficially owns 2,086,622 shares, or 4.9% of outstanding shares, and ceased to be a 5% beneficial owner.

• Sale Follows Mixed Clinical Data

  The divestiture comes days after the Phase 2 ZEPHYR trial delivered mixed results for ML-007C-MA in schizophrenia—the once-daily arm missed its primary endpoint—and weeks after the IRIS trial miss in autism.

• Contrasts with Catalyst4 Purchase

  This move contrasts sharply with a $15.3 million open-market purchase by 10% owner Catalyst4, Inc. between July 28-30, signaling divergent views among major shareholders.

auto_awesomeAnalysis · MPLT · Life Sciences

A major institutional investor, Novo Holdings A/S, sold 1.6 million shares of MapLight Therapeutics on July 30, trimming its stake from above 5% to 4.9%. The transaction, worth roughly $20.8 million, arrives just days after the company reported mixed Phase 2 ZEPHYR trial results and another 10% owner, Catalyst4, disclosed a $15.3 million purchase. The exit of a long-term healthcare backer raises questions about pipeline conviction, especially against the backdrop of the CFO's recent departure and the IRIS trial miss.